You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,981,064

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,981,064

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/459,743
Patent Claims:	1. A monoclonal antibody that binds to human PCSK9 at an epitope on PCSK9 that overlaps with an epitope that is bound by an antibody that comprises: a heavy chain variable region of the amino acid sequence in SEQ ID NO: 49; and a light chain variable region of the amino acid sequence in SEQ ID NO: 23, and wherein the epitope of said monoclonal antibody further overlaps with a site to which an EGFa domain of LDLR binds and thereby blocks binding between human PCSK9 and the EGFa domain of LDLR. 2. The monoclonal antibody of claim 1, wherein the monoclonal antibody further binds to human PCSK9 at an epitope on PCSK9 that overlaps with an epitope that is bound by a second antibody that comprises: a heavy chain variable region of the amino acid sequence in SEQ ID NO: 67; and a light chain variable region of the amino acid sequence in SEQ ID NO: 12. 3. The monoclonal antibody of claim 1, wherein said monoclonal antibody is a human or a humanized monoclonal antibody. 4. The monoclonal antibody of claim 1, wherein said monoclonal antibody is an IgG. 5. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises an intact immunoglobulin. 6. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a fragment of an intact immunoglobulin. 7. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a human kappa light chain. 8. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 157. 9. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a human lambda light chain. 10. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 156. 11. A monoclonal antibody that binds to human PCSK9 at an epitope on PCSK9 that overlaps with an epitope that is bound by an antibody that comprises: a heavy chain variable region of the amino acid sequence in SEQ ID NO: 67; and a light chain variable region of the amino acid sequence in SEQ ID NO: 12, and wherein the epitope of said monoclonal antibody further overlaps with a site to which an EGFa domain of LDLR binds and thereby blocks binding between human PCSK9 and the EGFa domain of LDLR. 12. The monoclonal antibody of claim 11, wherein said monoclonal antibody is a human or a humanized monoclonal antibody. 13. The monoclonal antibody of claim 11, wherein said monoclonal antibody is an IgG. 14. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises an intact immunoglobulin. 15. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises a fragment of an intact immunoglobulin. 16. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises a human kappa light chain. 17. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 157. 18. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises a human lambda light chain. 19. The monoclonal antibody of claim 11, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 156. 20. A monoclonal antibody that binds to human PCSK9 at an epitope on PCSK9 that overlaps with an epitope that is bound by an antibody that comprises: a heavy chain variable region of the amino acid sequence in SEQ ID NO: 467; and a light chain variable region of the amino acid sequence in SEQ ID NO: 469, and wherein the epitope of said monoclonal antibody further overlaps with a site to which an EGFa domain of LDLR binds and thereby blocks binding between human PCSK9 and the EGFa domain of LDLR. 21. The monoclonal antibody of claim 20, wherein the monoclonal antibody is an IgG. 22. The monoclonal antibody of claim 20, wherein the monoclonal antibody is a human or humanized antibody. 23. The monoclonal antibody of claim 20, wherein the monoclonal antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 156. 24. The monoclonal antibody of claim 20, wherein the monoclonal antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 157. 25. A monoclonal antibody that binds to human PCSK9 at an epitope on PCSK9 that overlaps with an epitope that is bound by an antibody that comprises: a heavy chain variable region of the amino acid sequence in SEQ ID NO: 87; and a light chain variable region of the amino acid sequence in SEQ ID NO: 13, and wherein the epitope of said monoclonal antibody further overlaps with a site to which an EGFa domain of LDLR binds and thereby blocks binding between human PCSK9 and the EGFa domain of LDLR. 26. The monoclonal antibody of claim 25, wherein said monoclonal antibody is an IgG. 27. The monoclonal antibody of claim 25, wherein the monoclonal antibody is a human or a humanized antibody. 28. The monoclonal antibody of claim 25, wherein the monoclonal antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 156. 29. The monoclonal antibody of claim 25, wherein the monoclonal antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 157.

Details for Patent 8,981,064

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	08/27/2015	⤷ Try a Trial	2027-08-23
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	07/08/2016	⤷ Try a Trial	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,981,064

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Argentina	068011	⤷ Try a Trial
Argentina	110799	⤷ Try a Trial
Australia	2008288791	⤷ Try a Trial
Australia	2013203677	⤷ Try a Trial
Australia	2013203685	⤷ Try a Trial
Australia	2013203689	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.